AI-Crafted mRNA vaccine takes on advanced cancers in first human trial

NCT ID NCT07560943

First seen May 03, 2026 · Last updated May 18, 2026 · Updated 4 times

Summary

This early-stage trial tests a personalized mRNA cancer vaccine designed by artificial intelligence. It is given as a shot directly into tumors for people with advanced solid cancers who have run out of standard options. The main goal is to check safety and find the right dose, while also watching for any signs that the vaccine shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The West China Hospital

    RECRUITING

    Chengdu, Sichuan, 646000, China

  • West China Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.